Immulina 400 Tablet contains Pidotimod 400 mg, an immunostimulant agent used to enhance the body's natural immune response. Pidotimod is a synthetic dipeptide that modulates both innate and adaptive immunity by promoting the activation and proliferation of T-lymphocytes, enhancing macrophage activity, and stimulating the production of cytokines. This immunomodulatory effect helps improve the body's defense mechanisms against recurrent respiratory tract infections, including bronchitis, sinusitis, and tonsillitis. Immulina 400 is indicated as an adjunct therapy in patients with weakened immune systems or those prone to frequent infections, particularly in pediatric and adult populations. The tablet is administered orally, with dosage and duration tailored according to clinical condition and physician recommendation. Clinical studies have demonstrated that Pidotimod reduces the frequency and severity of infections, thereby improving patient quality of life. It is generally well tolerated, with a low incidence of adverse effects such as gastrointestinal discomfort or allergic reactions. Immulina 400 should be used under medical supervision, especially in patients with autoimmune diseases or hypersensitivity to its components. This medication is not intended to replace standard antimicrobial therapy but serves as a supportive treatment to enhance immune competence.